Table 3.
LBNP Stage |
P Values |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
0 | 15 | 30 | 45 | 60 | LBNP | Sex | Interaction | PS-1 | P Value | |
Mean MCAv, cm/s | ||||||||||
Male | 60.4 ± 2.2 | 57.8 ± 2.1*† | 55.7 ± 2.4* | 53.4 ± 2.3* | 51.4 ± 1.9*† | <0.0001 | 0.02 | 0.77 | 42.1 ± 1.5 | P = 0.007 |
Female | 68.5 ± 3.2 | 66.2 ± 3.5 | 62.7 ± 3.3* | 60.2 ± 3.3* | 55.1 ± 4.2* | 51.1 ± 3.0 | ||||
Mean PCAv, cm/s | ||||||||||
Male | 43.6 ± 2.1 | 42.1 ± 2.0 | 40.8 ± 2.4* | 40.8 ± 2.4* | 37.4 ± 1.6* | <0.0001 | 0.38 | 0.99 | 32.1 ± 1.6 | P = 0.23 |
Female | 46.7 ± 2.4 | 44.3 ± 2.9 | 42.5 ± 2.6* | 41.1 ± 3.1* | 40.6 ± 3.1* | 35.8 ± 2.6 | ||||
Mean MCAv CVR, mmHg/(cm/s) | ||||||||||
Male | 1.6 ± 0.1 | 1.7 ± 0.1 | 1.7 ± 0.1 | 1.7 ± 0.1* | 1.7 ± 0.1* | <0.0001 | 0.04 | 0.79 | 1.9 ± 0.1 | P = 0.01 |
Female | 1.4 ± 0.1 | 1.5 ± 0.1 | 1.5 ± 0.1 | 1.5 ± 0.1 | 1.6 ± 0.1 | 1.6 ± 0.1 | ||||
Mean MCAv CVR, %Δ | ||||||||||
Male | – | 3.8 ± 1.6 | 5.3 ± 2.7* | 8.3 ± 3.0* | 9.1 ± 3.1* | <0.0001 | 0.29 | 0.65 | 18.1 ± 4.2 | P = 0.14 |
Female | – | 0.8 ± 1.2 | 3.8 ± 2.0 | 4.4 ± 2.3 | 5.9 ± 3.2 | 9.5 ± 3.6 | ||||
Mean PCAv CVR, mmHg/(cm/s) | ||||||||||
Male | 2.3 ± 0.1 | 2.3 ± 0.1 | 2.3 ± 0.1 | 2.2 ± 0.1 | 2.3 ± 0.1 | 0.003 | 0.63 | 0.30 | 2.4 ± 0.1 | P = 0.44 |
Female | 2.1 ± 0.1 | 2.2 ± 0.1 | 2.2 ± 0.1 | 2.3 ± 0.2* | 2.2 ± 0.2* | 2.3 ± 0.2 | ||||
Mean PCAv CVR, %Δ | ||||||||||
Male | – | 1.4 ± 1.2 | 1.0 ± 1.2 | 1.0 ± 1.3 | 3.3 ± 2.5 | 0.006 | 0.23 | 0.39 | 9.8 ± 4.0 | P = 0.81 |
Female | – | 2.3 ± 1.5 | 3.6 ± 2.5 | 5.9 ± 3.2* | 5.7 ± 3.6* | 8.3 ± 4.5 | ||||
ScO2, % | ||||||||||
Male | 69.5 ± 1.3† | 68.5 ± 1.3*† | 67.6 ± 1.3*† | 66.5 ± 1.4*† | 66.1 ± 1.5*† | <0.0001 | 0.01 | 0.08 | 64.2 ± 1.4 | P = 0.06 |
Female | 63.3 ± 1.9 | 62.4 ± 1.9* | 61.7 ± 2.0* | 60.6 ± 2.4* | 59.3 ± 3.6* | 59.6 ± 2.1 | ||||
HbO2, µM | ||||||||||
Male | 27.4 ± 1.5*† | 26.6 ± 1.7*† | 26.6 ± 1.6*† | 26.0 ± 1.9*† | 26.2 ± 2.6*† | <0.0001 | 0.0004 | 0.01 | 25.4 ± 1.6 | P = 0.002 |
Female | 38.4 ± 2.2* | 37.2 ± 2.1* | 36.1 ± 2.0* | 35.4 ± 2.2* | 34.1 ± 2.6* | 34.0 ± 1.9 | ||||
dHb, µM | ||||||||||
Male | 15.7 ± 1.0 | 15.8 ± 1.0 | 16.3 ± 1.0* | 16.7 ± 1.3* | 17.8 ± 1.9* | <0.0001 | 0.46 | 0.01 | 17.0 ± 1.1 | P = 0.30 |
Female | 16.5 ± 1.0 | 16.8 ± 1.1 | 17.1 ± 1.1 | 17.6 ± 1.2* | 17.4 ± 1.6* | 18.7 ± 1.1 | ||||
Respiratory Rate, breaths/min | ||||||||||
Male | 14.6 ± 0.8 | 13.7 ± 0.7 | 13.1 ± 0.8* | 13.1 ± 0.9* | 13.6 ± 1.1 | 0.0002 | 0.84 | 0.46 | 15.1 ± 1.1 | P = 0.53 |
Female | 14.9 ± 1.0 | 14.0 ± 0.8 | 13.5 ± 0.8 | 12.9 ± 0.8* | 12.1 ± 1.0* | 14.0 ± 1.3 | ||||
etCO2, mmHg | ||||||||||
Male | 40.3 ± 0.7 | 38.9 ± 0.8 | 37.2 ± 1.0* | 35.3 ± 1.3* | 34.6 ± 1.4* | <0.0001 | 0.90 | 0.63 | 27.8 ± 1.1 | P = 0.08 |
Female | 39.4 ± 0.9 | 38.7 ± 0.7 | 37.4 ± 0.8* | 35.3 ± 0.9* | 33.0 ± 1.6* | 30.9 ± 1.3 |
Data are presented as absolute and relative means ± SE. dHb, deoxygenated hemoglobin concentration; etCO2, end tidal carbon dioxide; HbO2, oxygenated hemoglobin concentration; LBNP, lower body negative pressure; MCAv, middle cerebral artery velocity; PCAv, posterior cerebral artery velocity; ScO2, cerebral oxygen saturation. PS-1 time point refers to the 1 min prior to presyncope. A two-factor linear mixed model analysis with repeated measures from baseline to −60 mmHg LBNP was performed, followed by Holm-corrected post hoc tests for multiple comparisons (run on the least squared means generated by the linear mixed model analysis).
*P ≤ 0.07 compared to baseline within a group. †P ≤ 0.09 between male and female groups. Sex differences at presyncope were assessed using unpaired t tests. Exact P values are reported for all comparisons.